๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma
Clinical trial register · China

Multiple Myeloma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 12 Hefei 1 Beijing 1 Zhengzhou 1 Jinan 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin12 Hefei1 Beijing1 Zhengzhou1 Jinan1
All 5 locations
Target enrolment
to

Multiple Myeloma trials in China

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-10-15
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
NCT07409454Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-07
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
NCT07249073Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
9
Tianjin
2025-03-28
Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NCT06880393Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2025-03-18
Recruiting
Clinical Study on the Safety and Efficacy of BCMA-CARTยฑASCT in Treating Young Multiple Myeloma Patients
NCT07169500Multiple Myeloma
DrugCar-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
NCT06793449Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-02-05
Recruiting
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
NCT06158269Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-12
Active, closed
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
NCT05850286Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-04-21
Active, closed
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-04-04
Recruiting
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2022-07-14
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Recruiting
National Longitudinal Cohort of Hematological Diseases
NCT04645199Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,300
Tianjin
2020-12-01
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/multiple-myeloma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Multiple Myeloma that also match the filters currently applied.

How many Multiple Myeloma trials are recruiting in China?

9 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Myeloma), 12 studies
PhaseStudiesRecruitingShare
Phase 28566.7%
Phase 1/22216.7%
Observational118.3%
Phase EARLY_PHASE1118.3%

Most active sponsors

Lead sponsors with the most studies (Multiple Myeloma)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China129
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.